Abstract: A compound of following formula (I): where: X is O or S; A is an aromatic (hetero)cycle having 5 to 10 atoms selected from among carbon and nitrogen atoms, optionally being substituted; R? is H or (C1-C6)alkyl group; R1, R2, R3, R4 and R5, the same or different, are selected from the group formed by: H, (C1-C6)alkyl groups and (C6-C10)aryl groups. The compound is for the treatment of neurodegenerative diseases.

Abstract: Provided are a fosaprepitant phosphate intermediate (IV) preparation method, a fosaprepitant phosphate intermediate (IV-A) and a method of (AA) for preparing fosaprepitant dimeglumine by using the intermediate (IV-A). IV: R1 and R2 are independently selected from C1-C7 alkyl groups or benzyl groups; IV-A: R1 and R2 are independently selected from C1-C7 alkyl groups, and R1 and R2 are not both benzyl groups.

Abstract: The invention relates to a manganese (II) complex, its preparation method and use. The structure of the complex is (R1R2R3R4A)2[MnX4], wherein R1, R2, R3 and R4 are identical or different, independently selected from alkyl, aryl, or heteroaryl; said alkyl, aryl, or heteroaryl can be optionally substituted with a substituent, and the substituent is preferably alkyl, aryl or heteroaryl; A is N, P, or As; X is optionally F, Cl, Br, or I. The present invention also relates to an organic light emitting diode, its preparation method and use, wherein the manganese (II) complex of the invention is used as a dopant in the light-emitting layer. The prepared organic light emitting diode exhibits high electrical-to-optical conversion efficiency which can be used for flat-panel displays and illuminations.

Abstract: A method for producing a cyclometalated iridium complex by allowing an iridium compound and an aromatic bidentate ligand to react each other. In particular, the method is characterized by allowing a ?-diketonate salt represented by General Formula (4) to coexist in a reaction system for reaction. By adding the ?-diketonate salt into the reaction system, stability of a reaction intermediate product between the iridium compound and the aromatic bidentate ligand improves. Therefore, yield of the cyclometalated iridium complex can improve. The cyclometalated iridium complex produced in accordance with the present invention is useful as a phosphorescent material for use in an organic EL element, for example.

Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.

Abstract: The invention describes stachyose compositions and methods to prepare such compositions with reduced or eliminated odor causing impurities, such as aldehydic impurities, contained within stachyose compositions that occur in nature or are caused during commercial processing.

Abstract: Reversibly blocked nucleoside analogues and methods of using such nucleoside analogues for sequencing of nucleic acids are provided.

Abstract: Provided are cyanogenic compositions for treating diseases, such as infectious diseases.

Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Abstract: The present invention is directed to a process for making Chloro-Substituted Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).

Abstract: Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides of general formula I, where R is selected from the group comprising furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl or chloro, and pharmaceutically acceptable salt thereof, their optical isomers and mixtures of such optical isomers.

Abstract: A group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, in which R shows strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.

Abstract: This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine (GalNAc) compounds, in particular phosphoramidite or phosphonoamidite molecules of formula (I) with only one GalNAc moiety (formula II) and to conjugates of nucleic acid molecules with such N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine. Wherein R1 is H or C1-6alkyl; R2 is a triphenylmethyl-based hydroxyl protecting group R3 is a phosphorus-containing group, particularly a phosphoramidite or a phosphonoamidite group, and K is represented by the general formula (II).

Abstract: Provided herein, in some embodiments, are methods and composition for the production of nucleoside triphosphates and ribonucleic acids.

Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.

Abstract: Novel compositions and methods for engineering wireframe architectures and scaffolds of increasing complexity by creating gridiron-like DNA structures (FIG. 1). A series of four-arm junctions are used as vertices within a network of double-helical DNA fragments. Deliberate distortion of the junctions from their most relaxed conformations ensures that a scaffold strand can traverse through individual vertices in multiple directions. DNA gridirons, ranging from two-dimensional arrays with reconfigurability to multilayer and three-dimensional structures and curved objects, can be assembled according the methods presented herein.

Abstract: An oxysterol or oxysterol-like compound is provided, which finds use in treating and/or targeting cancer.

Abstract: The present invention provides means and methods for functionalizing a polypeptide of interest at its C-terminus with an amino acid derivative.

Abstract: The present invention provides methods for extraction of amino acid-rich fractions from keratin-containing biological materials, and to amino acid-rich protein fractions generated by the methods described herein. The methods involve forming a reaction mixture with keratin containing material at a pH of 1.1 to 6.9. The reaction mixture is exposed to an energy source, such as microwaves, sufficient to degrade the keratin. The amino acid mixture which is subsequently extracted is substantially insoluble.

Abstract: Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions.

Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO: 4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.

Abstract: A method for producing a water-soluble protein concentrate from plant biomass is disclosed, comprising: obtaining plant matter from said plant biomass; drying said plant matter; grinding said dry plant matter; de-chlorophyllizing said ground dry plant matter; treating said ground dry de-chlorophyllized plant matter with water, thereby at least partially dissolving water-soluble protein content of said dry de-chlorophyllized plant matter and preparing an aqueous suspension of said dry de-chlorophyllized plant matter; separating said aqueous suspension of said dry de-chlorophyllized plant matter into a first neutral extract and a wet solid; and, drying said first neutral extract, thereby yielding a water-soluble protein concentrate. Also disclosed is a water-soluble protein concentrate produced by the method.

Abstract: The present invention describes rhomboid protease inhibitors having high specificity and inhibition characteristics providing novel antibiotics, anti-malarial pharmaceutical agents, and provides a strategy for designing RiBns (rhomboid-inhibiting boronates) to target rhomboid selectively in unrelated organisms.

Abstract: The present invention provides a phenylpropanamide derivative as represented by formula (I), a manufacturing method of the derivative, application of the derivative as a ?-opioid receptor (KOR) agonist, and application of the derivative for manufacturing a pharmaceutical product for treating and/or preventing pain or a pain-related disease.

Abstract: Present invention discloses particular peptide sequences of formula (I); (R1)(m)-Xaa1IXaa2T(Q)(p)(R2)(n) (I) (SEQ ID NO: 1); wherein R1, m, p, n, Xaa1, Xaa2, and R2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and/or treatment of mammal hair loss. Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).

Abstract: The present invention relates to a compound or a pharmaceutical salt thereof comprising a hexapeptide sequence of formula (I), its method of synthesis and its use in anticancer therapy. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Abstract: The present invention discloses a method for treating or/and preventing calcium deficiency-related diseases, which comprises administering a composition containing an effective amount of a peptide to a subject, wherein the peptide has an amino acid sequence as shown in SEQ ID NO. 3. The calcium ions are allowed to bind to the peptide and enter the cells of the patient, to achieve the effect of treating or/and preventing calcium deficiency-related diseases.

Abstract: The present disclosure provides bifunctional compounds including a polypeptide targeting moiety conjugated to a small molecule in a site-specific manner both of which bind to the same target protein resulting in potent and specific binding characteristics and methods of identifying such compounds.

Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.

Abstract: The invention discloses a method for producing surfactin by using Bacillus amyloliquefaciens, belonging to the technical field of industrial microorganisms. The invention synthesizes surfactin by using the screened Bacillus amyloliquefaciens CGMCC No. 12593, the yield is up to 9.43 g/L, and a fermentation process has the characteristics that the surfactin synthesis and the growth of the strain are synchronous without a lag period. The strain and the fermentation method provided by the invention will play an important role in the industrial production of surfactin and have broad application prospects.

Abstract: The invention relates to immunogenic compositions and vaccines containing a ZIKV protein or a polynucleotide encoding a Zika virus (ZIKV) protein and uses thereof. The invention also provides methods of treating and/or preventing a ZiKV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).

Abstract: This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.

Abstract: An antimicrobial peptide, the peptide comprising 2 to 20 variable domains, each variable domain is a sequence of 2 to 20 consecutive basic amino acids, wherein (a) the variable domains are separated from each other by a variable linker, (b) the variable linker can have 1 to 20 any amino acids other than two or more consecutive basic amino acids, and (c) the peptide has no more than 100 amino acids.

Abstract: A kappa light chain-binding polypeptide comprising or consisting essentially of one or more mutated binding domains of Peptostreptococcus Protein L.

Abstract: The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.

Abstract: The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, e.g., which include an annexin core domain to mediate efficient antigen delivery and antigen presentation in order to induce an antigen-specific immune response and/or to treat or prevent infectious diseases and/or cancer.

Abstract: The present invention relates to the treatment of cancer and to the prevention of cancer growth and/or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and/or cancers that develop and/or persist by evading host immune surveillance and/or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

Abstract: The disclosure provides a chimeric antigen receptor (CAR) comprising a modified hinge, transmembrane and/or intracellular domain disclosed herein. Some aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) comprising the costimulatory domain disclosed herein. Other aspects of the disclosure relate to cells comprising the CAR and use in a T cell therapy.

Abstract: The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

Abstract: Provided is polypeptide which derives from wild type TNF á and inhibits necrocytosis. The polypeptide contains 10-200 amino acid residues and a sequence QLVVPSE. Also provided is a pharmaceutical composition containing polypeptide. The polypeptide and the pharmaceutical composition containing the polypeptide are capable of inhibiting necrocytosis, thereby being used for treating inflammatory diseases.

Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.

Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role, such as inflammatory responses and autoimmune diseases. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.

Abstract: An insulin analogue comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. A proinsulin analogue or single-chain insulin analogue contains a B domain containing a cyclohexanylalanine substitution at position B24 and optionally contains additional amino-acid substitutions at positions A8, B28, and/or B29. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.

Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGEEHSV (SEQ ID NO: 1) derived from the MAGE-B2 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.

Abstract: A nucleic acid construct and mammalian cell harboring nucleic acids encoding an anti-CD7 chimeric antigen receptor are provided. Methods for treating cancer, in particular a hematologic cancer, using the nucleic acid construct or mammalian cell are also described.

Abstract: The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.

Abstract: Factor VIII variants and methods of use thereof are disclosed. In particular embodiments, Factor VIII variants exhibit one or more improvements compared to wild-type Factor VIII proteins, including wild-type Factor VIII proteins with a B-domain deletion (FVIII-BDD). Examples may include enhanced activity or function, secretion at increased levels by cells or are packaged more efficiently into viral vectors.

Abstract: An object of the present invention is to provide a cell culture method having excellent cell proliferation ability by a simple process and a medium and a culture medium kit used in the cell culture method described above. The present invention provides a cell culture method including: culturing cells in a medium in which a human-type recombinant protein is dissolved, in which the human-type recombinant protein is laminin, collagen, gelatin, or a variant thereof, and a content of the human-type recombinant protein in the medium is 0.01 ng/mL to 500 ?g/mL.